Therapeutic novelties of inhaled corticosteroids and bronchodilators in asthma

被引：12

作者：

Ricciardolo, Fabio L. M. ^{[1
]}

Blasi, Francesco ^{[2
]}

Centanni, Stefano ^{[3
]}

Rogliani, Paola ^{[4
]}

机构：

[1] Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy

[2] Univ Milan, Dept Pathophysiol & Transplantat, IRCCS Fdn Ca Granda, Milan, Italy

[3] Univ Milan, Resp Unit, San Paolo Hosp, Dipartimento Sci Salute, Milan, Italy

[4] Univ Roma Tor Vergata, Dept Syst Med, Unit Resp Clin Pharmacol, Rome, Italy

来源：

PULMONARY PHARMACOLOGY & THERAPEUTICS | 2015年 / 33卷

关键词：

Asthma; Inhaled corticosteroid; Bronchodilator; Long-acting beta 2 agonist; EXHALED NITRIC-OXIDE; LONG-ACTING BRONCHODILATORS; AIRWAY INFLAMMATION; ALVEOLAR MACROPHAGES; COMBINATION THERAPY; BRONCHIAL HYPERRESPONSIVENESS; BECLOMETHASONE DIPROPIONATE; FLUTICASONE PROPIONATE; LYMPHOCYTE-ACTIVATION; PRESCRIBED FENOTEROL;

D O I：

10.1016/j.pupt.2015.05.006

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Orally inhaled agents are a key therapeutic class for treatment of asthma. Inhaled corticosteroids (ICS) are the most effective anti-inflammatory treatment for asthma thus representing the first-line therapy and bronchodilators complement the effects of ICSs. A significant body of evidence indicates that addition of a beta 2-agonist to ICS therapy is more effective than increasing the dose of ICS monotherapy. In this paper, pharmacological features of available ICSs and bronchodilators will be reviewed with a focus on fluticasone propionate/formoterol fumarate combination which represents the one of the most powerful ICS acting together with the most rapid active LABA. (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：1 / 10

页数：10

共 125 条

[1] Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder
Abrams, Paul
Andersson, Karl-Erik
Buccafusco, Jerry J.
Chapple, Christopher
de Groat, William Chet
Fryer, Alison D.
Kay, Gary
Laties, Alan
Nathanson, Neil M.
Pasricha, Pankaj Jay
Wein, Alan J.
[J]. BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (05) : 565 - 578
[2] The dose-response characteristics of inhaled corticosteroids when used to treat asthma: An overview of Cochrane systematic reviews
Adams, N. P.
Jones, P. W.
[J]. RESPIRATORY MEDICINE, 2006, 100 (08) : 1297 - 1306
[3] Molecular mechanisms of corticosteroid resistance
Adcock, Ian M.
Barnes, Peter J.
[J]. CHEST, 2008, 134 (02) : 394 - 401
[4] Corticosteroid-insensitive asthma: molecular mechanisms
Adcock, IM
Lane, SJ
[J]. JOURNAL OF ENDOCRINOLOGY, 2003, 178 (03) : 347 - 355
[5] ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91
[6] Increased serum IL-17 is an independent risk factor for severe asthma
Agache, Ioana
Ciobanu, Cristina
Agache, Costel
Anghel, Mariana
[J]. RESPIRATORY MEDICINE, 2010, 104 (08) : 1131 - 1137
[7] Allen D. B., 2003, J ALLERGY CLIN IM S3, V112, P40
[8] Safety of inhaled corticosteroids in children
Allen, DB
[J]. PEDIATRIC PULMONOLOGY, 2002, 33 (03) : 208 - 220
[9] [Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD3534.PUB3
[10] Cysteinyl leukotrienes and 8-isoprostane in exhaled breath condensate of children with asthma exacerbations
Baraldi, E
Carraro, S
Alinovi, R
Pesci, A
Ghiro, L
Bodini, A
Piacentini, G
Zacchello, F
Zanconato, S
[J]. THORAX, 2003, 58 (06) : 505 - 509

← 1 2 3 4 5 6 7 8 9 10 →